Indolamine 2,3-dioxygenase expression by monocytes and dendritic cell populations in hepatitis C patients

Clinical and Experimental Immunology

Volumn 180, Issue 3, 2015, Pages 484-498

  Schulz, S ^a   Landi, A ^b   Garg, R ^a   Wilson, J A ^c   van Drunen Littel van den Hurk, S ^a,c  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Dendritic cell; Hepatitis C virus; IDO; Monocyte

Indexed keywords

INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE 1; INDOLEAMINE 2,3 DIOXYGENASE 2; KYNURENINE; N METHYLTRYPTOPHAN; TRYPTOPHAN; UNCLASSIFIED DRUG; 1-METHYLTRYPTOPHAN; AUTACOID; CHEMOKINE; CYTOKINE; MESSENGER RNA;

ADULT; ARTICLE; CELL MATURATION; CELL POPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; DONOR; EX VIVO STUDY; FEMALE; GENE EXPRESSION REGULATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; MONOCYTE; MYELOID DENDRITIC CELL; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; VIRUS STRAIN; AGED; ANALOGS AND DERIVATIVES; BLOOD; CASE CONTROL STUDY; DRUG EFFECTS; GENE EXPRESSION; GENETICS; GENOTYPE; HEPACIVIRUS; IMMUNOLOGY; LEUKOCYTE COUNT; METABOLISM; MIDDLE AGED; VIROLOGY; VIRUS LOAD; VIRUS REPLICATION; YOUNG ADULT;

ADULT; AGED; CASE-CONTROL STUDIES; CHEMOKINES; CYTOKINES; DENDRITIC CELLS; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INFLAMMATION MEDIATORS; KYNURENINE; LEUKOCYTE COUNT; MALE; MIDDLE AGED; MONOCYTES; RNA, MESSENGER; TRYPTOPHAN; VIRAL LOAD; VIRUS REPLICATION; YOUNG ADULT;

EID: 84929347350     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12586     Document Type: Article

References (52)

1. Bialek SR, Terrault NA. The changing epidemiology and natural history of hepatitis C virus infection. Clin Liver Dis 2006; 10:697-715.
2. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5:558-67.
3. McHutchison JG. Understanding hepatitis C. Am J Manag Care 2004; 10:S21-9.
4. The Medical Letter I. The Medical Letter for Drugs and Therapeutics, 2014:5-6.
5. Liu B, Woltman AM, Janssen HL, Boonstra A. Modulation of dendritic cell function by persistent viruses. J Leukoc Biol 2009; 85:205-14.
6. Landi A, Babiuk LA, van Drunen Littel-van den Hurk S. Dendritic cells matured by a prostaglandin E2-containing cocktail can produce high levels of IL-12p70 and are more mature and Th1-biased than dendritic cells treated with TNF-alpha or LPS. Immunobiology 2011; 216:649-62.
7. Wieder E. Dendritic cells: a basic review. International Society for Cellular Therapy 2003.
8. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 2004; 4:762-74.
9. Favre D, Mold J, Hunt PW et al. Tryptophan catabolism by indoleamine 2, 3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. Sci Transl Med 2010; 2:32ra6.
10. Boasso A, Herbeuval JP, Hardy AW et al. HIV inhibits CD4+ T-cell proliferation by inducing indoleamine 2, 3-dioxygenase in plasmacytoid dendritic cells. Blood 2007; 109:3351-9.
11. Larrea E, Riezu-Boj JI, Gil-Guerrero L et al. Upregulation of indoleamine 2, 3-dioxygenase in hepatitis C virus infection. J Virol 2007; 81:3662-6.
12. Higashitani K, Kanto T, Kuroda S et al. Association of enhanced activity of indoleamine 2, 3-dioxygenase in dendritic cells with the induction of regulatory T cells in chronic hepatitis C infection. J Gastroenterol 2013; 48:660-70.
13. Cozzi A, Zignego AL, Carpendo R et al. Low serum tryptophan levels, reduced macrophage IDO activity and high frequency of psychopathology in HCV patients. J Viral Hepat 2006; 13:402-8.
14. Lob S, Konigsrainer A, Zieker D et al. IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunol Immunother 2009; 58:153-7.
15. Qian F, Liao J, Villella J et al. Effects of 1-methyltryptophan stereoisomers on IDO2 enzyme activity and IDO2-mediated arrest of human T cell proliferation. Cancer Immunol Immunother 2012; 61:2013-20.
16. Landi A, Babiuk LA, Littel-van den Hurk SV. High transfection efficiency, gene expression, and viability of monocyte-derived human dendritic cells after nonviral gene transfer. J Leukoc Biol 2007; 82:849-60.
17. Song H, Li J, Shi S, Yan L, Zhuang H, Li K. Thermal stability and inactivation of hepatitis C virus grown in cell culture. Virol J 2010; 7:40.
18. Russell RS, Meunier JC, Takikawa S et al. Advantages of a single-cycle production assay to study cell culture-adaptive mutations of hepatitis C virus. Proc Natl Acad Sci USA 2008; 105:4370-5.
19. Castet V, Fournier C, Soulier A et al. Alpha interferon inhibits hepatitis C virus replication in primary human hepatocytes infected in vitro. J Virol 2002; 76:8189-99.
20. Cicinnati VR, Kang J, Sotiropoulos GC et al. Altered chemotactic response of myeloid and plasmacytoid dendritic cells from patients with chronic hepatitis C: role of alpha interferon. J Gen Virol 2008; 89:1243-53.
21. Takahashi K, Asabe S, Wieland S et al. Plasmacytoid dendritic cells sense hepatitis C virus-infected cells, produce interferon, and inhibit infection. Proc Natl Acad Sci USA 2010; 107:7431-6.
22. Ryan EJ, O'Farrelly C. The affect of chronic hepatitis C infection on dendritic cell function: a summary of the experimental evidence. J Viral Hepat 2011; 18:601-7.
23. Losikoff PT, Self AA, Gregory SH. Dendritic cells, regulatory T cells and the pathogenesis of chronic hepatitis C. Virulence 2012; 3:610-20.
24. Kunitani H, Shimizu Y, Murata H, Higuchi K, Watanabe A. Phenotypic analysis of circulating and intrahepatic dendritic cell subsets in patients with chronic liver diseases. J Hepatol 2002; 36:734-41.
25. Shiina M, Rehermann B. Cell culture-produced hepatitis C virus impairs plasmacytoid dendritic cell function. Hepatology 2008; 47:385-95.
26. Decalf J, Fernandes S, Longman R et al. Plasmacytoid dendritic cells initiate a complex chemokine and cytokine network and are a viable drug target in chronic HCV patients. J Exp Med 2007; 204:2423-37.
27. Mansour H, Laird ME, Saleh R et al. Circulating plasmacytoid dendritic cells in acutely infected patients with hepatitis C virus genotype 4 are normal in number and phenotype. J Infect Dis 2010; 202:1671-5.
28. Albert ML, Decalf J, Pol S. Plasmacytoid dendritic cells move down on the list of suspects: in search of the immune pathogenesis of chronic hepatitis C. J Hepatol 2008; 49:1069-78.
29. Von Bubnoff D, Scheler M, Wilms H, Fimmers R, Bieber T. Identification of IDO-positive and IDO-negative human dendritic cells after activation by various proinflammatory stimuli. J Immunol 2011; 186:6701-9.
30. de Jong RA, Nijman HW, Boezen HM et al. Serum tryptophan and kynurenine concentrations as parameters for indoleamine 2, 3-dioxygenase activity in patients with endometrial, ovarian, and vulvar cancer. Int J Gynecol Cancer 2011; 21:1320-7.
31. Suzuki Y, Suda T, Furuhashi K et al. Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer. Lung Cancer 2010; 67:361-5.
32. Lob S, Konigsrainer A, Schafer R, Rammensee HG, Opelz G, Terness P. Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells. Blood 2008; 111:2152-4.
33. Okamoto T, Tone S, Kanouchi H, Miyawaki C, Ono S, Minatogawa Y. Transcriptional regulation of indoleamine 2, 3-dioxygenase (IDO) by tryptophan and its analogue: down-regulation of the indoleamine 2, 3-dioxygenase (IDO) transcription by tryptophan and its analogue. Cytotechnology 2007; 54:107-13.
34. Agaugue S, Perrin-Cocon L, Coutant F, Andre P, Lotteau V. 1-Methyl-tryptophan can interfere with TLR signaling in dendritic cells independently of IDO activity. J Immunol 2006; 177:2061-71.
35. Inaba T, Ino K, Kajiyama H et al. Role of the immunosuppressive enzyme indoleamine 2, 3-dioxygenase in the progression of ovarian carcinoma. Gynecol Oncol 2009; 115:185-92.
36. Revie D, Salahuddin SZ. Human cell types important for hepatitis C virus replication in vivo and in vitro: old assertions and current evidence. Virol J 2011; 8:346.
37. Klenerman P, Thimme R. T cell responses in hepatitis C: the good, the bad and the unconventional. Gut 2012; 61:1226-34.
38. Revie D, Salahuddin SZ. Role of macrophages and monocytes in hepatitis C virus infections. World J Gastroenterol 2014; 20:2777-84.
39. Inokuchi M, Ito T, Uchikoshi M et al. Infection of B cells with hepatitis C virus for the development of lymphoproliferative disorders in patients with chronic hepatitis C. J Med Virol 2009; 81:619-27.
40. Liang H, Russell RS, Yonkers NL et al. Differential effects of hepatitis C virus JFH1 on human myeloid and plasmacytoid dendritic cells. J Virol 2009; 83:5693-707.
41. Pham TN, MacParland SA, Mulrooney PM, Cooksley H, Naoumov NV, Michalak TI. Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. J Virol 2004; 78:5867-74.
42. Marukian S, Jones CT, Andrus L et al. Cell culture-produced hepatitis C virus does not infect peripheral blood mononuclear cells. Hepatology 2008; 48:1843-50.
43. Reske A, Pollara G, Krummenacher C, Katz DR, Chain BM. Glycoprotein-dependent and TLR2-independent innate immune recognition of herpes simplex virus-1 by dendritic cells. J Immunol 2008; 180:7525-36.
44. Auffermann-Gretzinger S, Keeffe EB, Levy S. Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection. Blood 2001; 97:3171-6.
45. Saito K, Ait-Goughoulte M, Truscott SM et al. Hepatitis C virus inhibits cell surface expression of HLA-DR, prevents dendritic cell maturation, and induces interleukin-10 production. J Virol 2008; 82:3320-8.
46. MacDonald AJ, Semper AE, Libri NA, Rosenberg WM. Monocyte-derived dendritic cell function in chronoc hepatitis C is impaired at physiological numbers of dendritic cells. Clin Exp Immunol 2007; 148:494-500.
47. Terness P, Bauer TM, Rose L et al. Inhibition of allogeneic T cell proliferation by indoleamine 2, 3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J Exp Med 2002; 196:447-57.
48. Braun D, Longman RS, Albert ML. A two-step induction of indoleamine 2, 3 dioxygenase (IDO) activity during dendritic-cell maturation. Blood 2005; 106:2375-81.
49. Lanzinger M, Jurgens B, Hainz U et al. Ambivalent effects of dendritic cells displaying prostaglandin E2-induced indoleamine 2, 3-dioxygenase. Eur J Immunol 2012; 42:1117-28.
50. Krause P, Singer E, Darley PI, Klebensberger J, Groettrup M, Legler DF. Prostaglandin E2 is a key factor for monocyte-derived dendritic cell maturation: enhanced T cell stimulatory capacity despite IDO. J Leukoc Biol 2007; 82:1106-14.
51. von Bergwelt-Baildon MS, Popov A, Saric T et al. CD25 and indoleamine 2, 3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition. Blood 2006; 108:228-37.
52. Waris G, Siddiqui A. Hepatitis C virus stimulates the expression of cyclooxygenase-2 via oxidative stress: role of prostaglandin E2 in RNA replication. J Virol 2005; 79:9725-34.